Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.64 |
| ▸ | SQLE | Q14534 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 2/20 | 0.53 |
| ▸ | FNTB | P49356 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12555811 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL12412583 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL296281 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL3791172 | 1.00 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL3503739 | 0.98 | KMT2A (0.68) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL1472304 | 0.98 | KMT2A (0.68) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL332318 | 0.98 | KMT2A (0.68) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL8064939 | 0.86 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL28619973 | 0.86 | KMT2A (0.81) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| Squalene SCHEMBL28619974 | 0.86 | KMT2A (0.81) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069230-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | THE BROAD INSTITUTE, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| EP-3330252-B1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES INC (US) | 2020-02-12 | — | — | EP | disclosed |
| WO-2019200224-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | THE BROAD INSTITUTE, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| EP-3330252-A2 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | Signum Biosciences, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9012693-B2 | Process for the preparation of vitamin K2 | KAPPA BIOSCIENCE AS (NO) | 2015-04-21 | — | — | US | disclosed |
| WO-2013016531-A2 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER | PURDUE RESEARCH FOUNDATION (US) | 2013-01-31 | — | — | WO | disclosed |
| US-8097722-B2 | Inhibitors of polyisoprenylated methylated protein methyl esterase | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (US) | 2012-01-17 | — | — | US | disclosed |
| US-7897604-B2 | Inhibitors of polyisoprenylated methylated protein methyl esterase | FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090253640-A1 | INHIBITORS OF POLYISOPRENYLATED METHYLATED PROTEIN METHYL ESTERASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-08 | — | — | US | disclosed |
| US-4067910-A | HEATING ALLYL XANTHOGENATE | GIVAUDAN CORPORATION (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069230-A1 | SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES | ABCC1, TSG101, BRCA1 | KMT2A 3051/4885MAPT 4086/4885MEN1 3603/4885 |
| US-20090253640-A1 | INHIBITORS OF POLYISOPRENYLATED METHYLATED PROTEIN METHYL ESTERASE | RCE1, PPME1, EMG1 | KMT2A 607/4885MAPT 4377/4885MEN1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.